A phase 3 trial evaluating pimavanserin (Acadia) for the treatment of dementia-related psychosis has been stopped early due to positive findings in a planned interim efficacy analysis.
Use of hearing aids is associated with lower risks for being diagnosed with Alzheimer disease, dementia, depression, anxiety, and injurious falls among elderly adults diagnosed with hearing loss.
Patients with Alzheimer disease who participated in elastic resistance exercises showed changes in depressive symptoms, muscle function, and muscle mass.
Use of acetylcholinesterase inhibitors to manage dementia-related behavioral and psychological symptoms in people with Alzheimer disease may reduce the need for psychotropic medications.
Results from a study evaluating the safety and efficacy of suvorexant (Merck) for the treatment of insomnia in patients with mild to moderate Alzheimer disease dementia were presented at the AAN meeting.
Avanir announced data from the phase 3 clinical program that evaluated AVP-786 (deudextromethorphan hydrobromide/quinidine sulfate) for the treatment of moderate-to-severe agitation in patients with Alzheimer dementia.
Biogen and Eisai have made the decision to discontinue two phase 3 trials evaluating aducanumab for the treatment of mild cognitive impairment due to Alzheimer disease (AD) and mild AD dementia.
Having affected first-degree, second-degree, or third-degree relatives is associated with an increased risk for Alzheimer disease.
Researchers analyzed the cross-sectional relationships among regional tau, β-amyloid, and cortical thickness and neuropsychological function in Alzheimer disease.
Differences in Alzheimer biomarkers suggest possible race-dependent biological mechanisms that contribute to expression of disease.